<DOC>
	<DOCNO>NCT00483847</DOCNO>
	<brief_summary>The primary objective study determine incidence pattern serious infection , malignancy , serious adverse event ( SAEs ) participants multiple sclerosis ( MS ) treat TYSABRI ( natalizumab ) .</brief_summary>
	<brief_title>TYGRIS - ROW : TYSABRI Global Observational Program Safety - Rest World</brief_title>
	<detailed_description>The TYSABRI Global Observational Program Safety Rest World ( TYGRIS - ROW ) safety observational cohort program design obtain long-term safety data multiple sclerosis ( MS ) participant treat TYSABRI clinical practice set country United States Canada . The Prescribing Physician collect participant information routine clinic visit ( use standard data collection tool ) approximately 6-month interval 5 year first TYSABRI infusion .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key All Multiple Sclerosis ( MS ) participant Rest World ( ROW ) prescribe receive TYSABRI normal clinical practice center take part study eligible participate TYGRIS ROW . Participants must receive least 1 3 infusion TYSABRI . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>TYGRIS - Rest World ( ROW )</keyword>
	<keyword>TYSABRI</keyword>
	<keyword>natalizumab</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>